Cipla is moving forward with the sale of Afrezza, an insulin patients inhale from the mouth, aiming to offer a painless alternative to injectable insulin. The big question is whether this inhaled option can gain traction against entrenched global players and established injection-based routines in diabetes care.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
